Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received a suspension order on the drug license of one of its stores located at Nippo Centre in Andhra Pradesh. The order was issued by the Drug Control Administration, Nellore, under Rule 65 of the Drugs and Cosmetics Act, 1940, and suspends the license for seven days. The order was received on July 9, 2025. The company estimates a potential revenue loss of around Rs 3.40 lakhs from the seven-day suspension. The disclosure has been made under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.
The impact is negligible — this is a single-store, seven-day suspension with a potential revenue loss of only about Rs 3.40 lakhs, which is immaterial to Medplus's overall business. Shareholders are unlikely to see any meaningful effect on operations or the stock price.